Abstract
Recently, a group of microRNAs (miRNAs), the miR-200 family (miR-200s) has been found to be deregulated in multiple types of cancers, in which this family of miRNAs was demonstrated to play a pivotal role in tumor initiation, maintenance, malignant metastasis and chemotherapy resistance. By targeting several central inducers of the epithelial-to-mesenchymal transition (EMT), e.g. ZEB1, ZEB2 and SLUG, miR-200s are currently recognized as master regulators of EMT, thereby suppressing cancer invasion and metastasis. The involvement of miR-200s in angiogenesis has also been reported, and they were found to directly target VEGF-A, FLT1/VEGFR1 and KDR/VEGFR2, three key components of the VEGF signaling pathway. Importantly, miR-200s also modulate the self-renewal ability of cancer stem cells by targeting BMI1 and SUZ12. Aberrant expression of miR-200s has been shown to confer chemoresistant properties to various kinds of cancers. Thus, miR-200s, by playing critical and pleiotropic roles in malignancies, are promising targets for cancer therapy. Notably, it has been shown that several types of natural agents and herbal extracts could be employed to manipulate the expression of miR-200s, making the targeting of miR-200s in cancer therapy more clinically attractive. Nevertheless, a very recent study reported a metastasis-promoting role of miR-200s in breast cancer; thus, careful assessment should be conducted before applying therapeutic interventions using miR-200s as treatment targets. In this review, we will focus on our emerging understanding of the roles of miR- 200s in cancer, specifically their therapeutic potential in treating cancer.
Keywords: miR-200 family, epithelial-to-mesenchymal transition, tumor metastasis, cancer stem cells, angiogenesis, cancer therapeutics.
Current Pharmaceutical Design
Title:A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Volume: 20 Issue: 11
Author(s): Hai-Feng Zhang, Li-Yan Xu and En-Min Li
Affiliation:
Keywords: miR-200 family, epithelial-to-mesenchymal transition, tumor metastasis, cancer stem cells, angiogenesis, cancer therapeutics.
Abstract: Recently, a group of microRNAs (miRNAs), the miR-200 family (miR-200s) has been found to be deregulated in multiple types of cancers, in which this family of miRNAs was demonstrated to play a pivotal role in tumor initiation, maintenance, malignant metastasis and chemotherapy resistance. By targeting several central inducers of the epithelial-to-mesenchymal transition (EMT), e.g. ZEB1, ZEB2 and SLUG, miR-200s are currently recognized as master regulators of EMT, thereby suppressing cancer invasion and metastasis. The involvement of miR-200s in angiogenesis has also been reported, and they were found to directly target VEGF-A, FLT1/VEGFR1 and KDR/VEGFR2, three key components of the VEGF signaling pathway. Importantly, miR-200s also modulate the self-renewal ability of cancer stem cells by targeting BMI1 and SUZ12. Aberrant expression of miR-200s has been shown to confer chemoresistant properties to various kinds of cancers. Thus, miR-200s, by playing critical and pleiotropic roles in malignancies, are promising targets for cancer therapy. Notably, it has been shown that several types of natural agents and herbal extracts could be employed to manipulate the expression of miR-200s, making the targeting of miR-200s in cancer therapy more clinically attractive. Nevertheless, a very recent study reported a metastasis-promoting role of miR-200s in breast cancer; thus, careful assessment should be conducted before applying therapeutic interventions using miR-200s as treatment targets. In this review, we will focus on our emerging understanding of the roles of miR- 200s in cancer, specifically their therapeutic potential in treating cancer.
Export Options
About this article
Cite this article as:
Zhang Hai-Feng, Xu Li-Yan and Li En-Min, A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets, Current Pharmaceutical Design 2014; 20 (11) . https://dx.doi.org/10.2174/13816128113199990519
DOI https://dx.doi.org/10.2174/13816128113199990519 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology Characterization of Solid Lipid Nanoparticles Containing Caffeic Acid and Determination of its Effects on MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery Antiepileptics and the Treatment of Neuropathic Pain: Evidence from Animal Models
Current Pharmaceutical Design Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Familial Colorectal Cancer Type X
Current Genomics Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Preface
Current Pharmaceutical Design Search for Distinctive Markers in DNT and Cortical Grade II Glioma in Children: Same Clinicopathological and Molecular Entities?
Current Topics in Medicinal Chemistry Micro-RNA (miRNA): A Biomarker to Identify Novel Compounds in Drug Discovery and Delivery for Cancer Therapy
Current Drug Discovery Technologies A New Synthetic Spiroketal: Studies on Antitumor Activity on Murine Melanoma Model In Vivo and Mechanism of Action In Vitro
Anti-Cancer Agents in Medicinal Chemistry Outcome-Dependent Global Similarity Analysis of Imbalanced Core Signaling Pathways in Ischemic Mouse Hippocampus
CNS & Neurological Disorders - Drug Targets An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Meet Our Editorial Board Member
Current Protein & Peptide Science Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs